Olgram, a Brehan, France-based biotechnology company developing marine molecules for the prevention and control of bacterial infections, raised €1.5m in seed funding.
The backers were not disclosed.
Founded in 2019 and led by Pierre Rocheteau, CEO, Olgram is a biotechnology company developing marine molecules for the prevention and control of chronic bacterial infections. The company has 2 product candidates targeting infections. Olgram will first focus its efforts on cystic fibrosis, an orphan disease in which 35% of patients suffer from chronic Pseudomonas aeruginosa infections in adulthood (a pathogenic bacterium) leading to their premature death. In a second phase, the company will target nosocomial infections in immunocompromised patients after head trauma.
The company intends to use the funds to accelerate the development of anti-infectious molecules capable of eliminating the bacteria responsible for chronic relapses. To do so, Olgram is characterizing, modifying and optimizing peptides and a marine molecule, MSP (Marine Sulfated Polysaccharide).